An Open-label Pharmacokinetic and Safety Study of Cabazitaxel in Patients With Solid Tumors With Moderately and Severely Impaired and With Normal Renal Function.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Sanofi
- 03 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 May 2012 Actual initiation date changed from Feb 2012 to Apr 2012, as reported by ClinicalTrials.gov.
- 22 May 2012 Planned end date changed from 1 Jul 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.